DSIP showed potential in early animal and small human trials to decrease sleep latency and improve the depth and efficiency of sleep
The multi-dose vial format reduces waste and supports cost-effective care delivery across multiple patient visits
The dihexa half life ranges from approximately one to three hours in plasma, with subcutaneous administration extending clearance time slightly compared to intraperitoneal routes
Previous research has shown that excessive nitric oxide (NO) production, increased levels of oxidative stress, and cerebrovascular hypoperfusion are mayor pathomechanisms responsible for AD (Lepara et al
Dong, B., Zhou, G., Lin, Y., Yu, C., Wang, J., Sun, C., et al., Appl
Publisher Responsibility Disclaimer: The publisher has made reasonable efforts to ensure accuracy at the time of publication but does not guarantee completeness or timeliness of the information provided